Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for neoplasia early stage of intracranial glioma, and detection method and application

Abstract

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker, and a method for performing n-situ hybridization detection on messenger ribonucleic acid (mRNA) of a circulating immune complex (CIC), which is closely related with the pathologic evolution of the early stage of intracranial glioma by using the kit. The method comprises the following steps of: 1) contacting RNA to be detected in substrate and a hybridization probe under the condition that the hybridization probe and a target sequence can form a stable hybridization complex to form the hybridization complex; and (2) detecting the hybridization complex. By the kit and the detection method, the gen expression level can be detected at the mRNA level; the obtained detection index is earlier than the detection indexes of medical imaging and the conventional clinical chemistry; real mRNA-level screening of the earlier stage of canceration can be realized; and meanwhile, the detection method is simple and convenient, and low in cost, and can be conveniently popularized and applied in county hospitals.

Description

technical field [0001] The present invention relates to the field of biological detection, more specifically, relates to the detection technology related to the change of mRNA expression (pathological evolution process) of precancerous changes. Background technique [0002] According to the information provided by authoritative organizations at home and abroad, there are 2.6 million new cancer cases in my country every year, nearly 2.1 million deaths, and more than 7 million patients. Globally, there are 8 million new cancer patients every year, nearly 8 million deaths, and more than 8,400 patients. Ten thousand people, the number will double by 2020, this is a set of terrible figures. The cost of cancer diagnosis and treatment is getting higher and higher. The annual treatment cost of cancer patients is 200,000 yuan (may be higher in poor areas, and 200,000 yuan in developed areas). For more than 7 million patients, the annual cost is 1.4 trillion yuan. 35% of the cost is a...

AI Technical Summary

Problems solved by technology

[0003] In 2005, eight institutions including the US Institutes of Health, the Cancer Institute, and the Centers for Disease Control and Prevention made an annual report, reviewing the anti-cancer war launched in 1972. The report believed that human beings had failed in the anti-cancer war, and the conclusion was that cancer died The rate did not decrease, and it listed several factors that caused the failure of the anti-cancer war: 1. Tumor cell heterogeneity (polymorphism); 2. Tumor cell drug resistance; 3. Incomplete design of anti-cancer drugs (animals) unscientific model design), etc.

[0014] In view of the current clinical diagnosis of cancer (imaging medicine and biochemical indicators are all diagnosed after tumor formation) is a late diagnosis, treatment is also a late treatment, leading to a treatment model that does not reduce mortality

Images